R. Villanueva

发表

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Rehabilitation Needs of the Cancer Patient

R. Villanueva, 1975, Southern medical journal.

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

M. Gil-Gil, I. Morilla, S. Pernas, 2019, BMC Pharmacology and Toxicology.

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

M. Gil-Gil, I. Morilla, S. Pernas, 2019 .

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

L. de la Peña, E. Adrover, P. Zamora, 2019, Therapeutic advances in medical oncology.

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Sung-Bae Kim, S. Loi, A. Bardia, 2020 .

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

L. Chow, A. Bardia, N. Harbeck, 2019, Journal of Clinical Oncology.

Severe visual loss in a breast cancer patient on chemotherapy

R. Casaroli-Marano, J. Giralt, A. Rey, 2012, Medical Oncology.

Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases

M. Simó, M. Gil-Gil, R. Velasco, 2021, Clinical and Translational Oncology.

LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

Sung-Bae Kim, V. Valero, A. Tan, 2015 .

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress).

T. Pluard, J. O’Shaughnessy, U. Brown-Glaberman, 2022, Journal of Clinical Oncology.

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

A. Bardia, J. Spoerke, J. Giltnane, 2018 .

Abstract PS12-08: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)

M. Juan, G. Nuovo, M. Coffey, 2021 .

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

M. Gil-Gil, I. Morilla, S. Pernas, 2019, BMC Pharmacology and Toxicology.